about
Structural domains of vault proteins: a role for the coiled coil domain in vault assemblyCancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitorsTreatment of relapsed and refractory multiple myelomaAmerican Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic CeThe myeloma stem cell concept, revisited: from phenomenology to operational termsHigh EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patientsVaults: a ribonucleoprotein particle involved in drug resistance?Distinct expression profiles of the peripheral cannabinoid receptor in lymphoid tissues depending on receptor activation statusAge and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.Management of multiple myeloma with bortezomib: experts review the data and debate the issues.ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients.Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial.A practical update on the use of bortezomib in the management of multiple myeloma.Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemiaThalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.International staging system for multiple myeloma.Vault mobility depends in part on microtubules and vaults can be recruited to the nuclear envelope.Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.High-dose daunorubicin in older patients with acute myeloid leukemia.Cytarabine dose for acute myeloid leukemia.Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.
P50
Q24292333-56FD2642-0D54-4C84-87F2-9AB8E945824AQ24305602-4E8A5C71-D858-4F46-B393-4CF1AD2763AFQ26749180-94ACB05A-9D4D-4852-B1DF-70393C79CD5AQ26782868-360116BA-CE9B-490B-9823-AA63452FC4A8Q28076070-A966684E-4B3E-4471-A05D-6AA6AF2B03A8Q28209409-AEC4151B-477D-429B-9275-E29B1E3DB166Q28212334-2BC34314-6E4A-4D37-A46C-FDFE022A565FQ28242535-3F583669-DB47-4A0B-A1E9-A3998CD6860DQ30595175-077859D3-FF6C-4042-8811-37C808C77666Q30756778-A1822309-A72A-4E9E-A000-9D82D86A929FQ31098282-7D9E6F7B-0E4E-4DF4-ABDB-13C458D4D8F1Q33263989-B5FCEF6C-86A6-442E-93FF-8E332B18C243Q33264716-28C8F4BA-B03C-4E20-9AF6-700B14BB38E2Q33369837-63B3BBCF-B2CA-4EA9-ACF8-94AFFBDC223BQ33374964-463710CB-F59D-4B86-BA4F-E952EAFCDF27Q33376149-31BBF1E7-A54C-4905-8212-A847C37F44FEQ33380816-8A819278-0F46-49A9-9E03-A18A737584BDQ33391550-BB552596-E611-4CA4-9C38-08D74C9DE722Q33410172-569F7275-702D-4981-A5B4-F645F56A26CCQ33434817-768E9EB2-4AAE-447D-BACF-87D7454B755DQ33435458-96DF3A86-B271-4349-90A6-72951B8B6B43Q33558161-AE223760-CDA7-49FB-979C-EE8D22128CCCQ33701381-F740F85F-A7D9-4E12-909F-C9CF19B43D61Q33886167-1C3E1A6B-DF31-4951-8D5B-B86EC4F27C81Q33931651-9C8E43A8-BB68-4BB5-98E3-47DD49004508Q34130459-CB46B036-BF99-4B05-963E-B6CE011BB581Q34293391-6FAF7178-3901-49C4-B159-F2F39E2E93BFQ34372086-C044827F-3FEF-4697-861C-846058DA2ED1Q34408882-41C1B73F-DFC0-4C0B-92B7-E57ADDED3055Q34470468-D9C4BB39-8ECF-453B-A47C-608086C6CA88Q34536382-E7FE7CBF-6A5D-475D-B99B-8068010385ACQ34590091-EFC7F784-F3FD-448F-907A-0493EC5F8A9CQ34595043-9FBFEE36-3BB4-4940-8922-D6351DCB10D8Q34603644-6BE23EA6-2E9E-49F6-8E74-AF07F12D1FDAQ34612117-D851F625-A380-4CAE-B5F3-449272B280CFQ34627648-519CA65E-D9B5-4279-966D-DD36F28FDB47Q34656801-1753FA6B-313E-4890-BB27-B3D78AA8BE86Q34677689-9A4E47AC-BAE3-4CA2-A8BC-1C616E8A72F1Q34798095-E52A7563-5683-4F4E-A976-2E509C49A87CQ34990174-9912270B-7098-4B4B-BC4E-788D1753E874
P50
name
Pieter Sonneveld
@en
Pieter Sonneveld
@nl
type
label
Pieter Sonneveld
@en
Pieter Sonneveld
@nl
prefLabel
Pieter Sonneveld
@en
Pieter Sonneveld
@nl